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1. Summary
The haemostatic-thrombotic system (HTS) can be inhibited at dozens of
different sites by hundreds of different drugs. The ideal antithrombotic is
an inhibitor that downregulates the HTS without causing bleeding or
other side-effects, and that can be given orally in a fixed dose. These are
pharmacological criteria. Indeed, the three current therapies (heparins,
oral anticoagulant therapy and aspirin) act by completely different
mechanisms.It is not the mechanism of inhibitionwhichis importantbut
the pharmacological properties of the inhibitor; no compound has been
found thatinhibits theHTS and doesnot show anantithrombotic effect.
The HTS is a non-linear system containing a number of nested positive
and negative feedback loops. At the present state of knowledge it is
impossible to predict the effect of inhibition of a single reaction on the
response of the complete system. For this reason one cannot predict the
antithrombotic potency of a compound from its biochemical properties. It
is shown that clotting tests, measurement of platelet aggrega-
tion/adhesion or tests of individual functions within the system are only
of limited use. Antithrombotics therefore should be evaluated by their
action on a representative function test of the complete HTS. Such a test is
not routinely available at the moment. Two promising possibilities are
flow chambers using non-anticoagulated blood and thrombin generation
in blood or platelet rich plasma (PRP).
2. Background
Thrombosis is caused by the same mechanism that causes haemostasis.
Administering antithrombotic drugs therefore requires careful manipu-
Iation of the balance between thrombosis and bleeding. For the safe use of
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antithrombotic drugs, we need a probe for the functional status of the HTS. Such a test is not
routinely available at this moment. Bleeding times are hopelessly inaccurate [1] and clotting
times are to be considered surrogate variables of limited use. There is no general test to
indicate hypercoagulability and thrombosis risk, or to monitor the effect of antithrombotic
treatment. Current management of thrombosis is like managing diabetes by the taste of the
urine, or hypertension with only a pulse to feel.
This situation has an immediate influence on the search for new antithrombotic drugs.
There is no easy, valid laboratory test to indicate therapeutic efficacy or optimal dosage. The
research goal is defined in terms like 
'doubling the activated partial thromboplastin time
(aPTT)' or 'inhibition of platelet aggregation' that have, at the best, a semiquantitative
relation to haemostasis and thrombosis. Further testing is in animal thrombosis rnodels
and, eventually, clinical kials.
In this article we will defend the position that it is unimportant how the function of the HTS
is inhibited as long as the inhibition fulfils certain pharmacological criteria. Consequently,
we will not dwell in detail on individual mechanisms of inhibition or on inhibitor design.
Rather we will stress the importance of assessing HTS function as a whole.
3. Medical need
In recent years it has been firmly established that virtually every arterial occlusive event
(such as myocardial or cerebral infarction) is due to the formation of a local thrombus on a
damaged intemal surface of the vessel. Thrombin plays an all-important role in this process
12-61. Adamaged wall exposes triggers for thrombosis, such as tissue factor (TF) present in
the smooth muscle cells of neointima [7], in the adventitia and in the plaque [8-10], as well as
the platelet-activating collagen surface [11]. Non-occlusive arterial thrombosis may lead to
downstream occlusion if the thrombus is carried with the bloodstream. Lr strategic
positions, such as the carotid arteries, this may have serious consequences. Arterial
thrombosis is not only the consequence of atherosclerosis; through microthrombus
formationit also plays a role inthe development of arterialwall degeneration. Furthermore,
venous thrombosis and its sequelae, ranging from sudden death due to pulmonary
embolism to chronic leg-ulcers, is not a negligible source of illness. At this moment, in the
Westem World, arterial and venous thrombosis and atherosclerosis together are respon-
sible for well over 50"h of allmortality and serious morbidity. In a few decades this will be
the case worldwide [12]. Good antithrombotic drugs, therefore, are a necessity.
3.l Existing treatment
3.l.l Heparins
Heparins, either unfractionated (UFH) or of the low molecular weight type (LMWH) [14],
reduce the incidence of thrombosis by about 50%. They have the drawback of parenteral
administration. They may cause antithrombin (AT) deficiency, thrombocytopenia,
bleeding and a few more rare side-effects. The methods for laboratory control of heparin
dosage, notably the aPTT, are inadequate. The question of whether adapted doses of
heparin would do better than current practice remains unsolved because control methods
to guide the adaptation are not available. Prolonged heparin treatment, in particular with
UFH, is not favoured.
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3. 1.2 Oral anticoagulation
oral anticoagulation (oAC) is maintained with coumarin congeners, i.e., anti-vitamin Kdrugs' They inhibit the oxidation reduction cycle of vitamin K;-i the liver, required for thenormal y-carboxylation of the clotting Factors tr, vII, IX and X, protein C and protein s.There are large variations in individual need and many drug interactions (e.g., with
sleeping pills and alcohol). Therefore, regular control oi*," level of anticoagulation isnecessary' This can be readily carri ed outoiadetermination of the thromboplasti"n time and
expressing the result as an intemational normalised. ratio (INR).
3.1.3 Aspirin
A-spirin is the only antiplatelet drug in general use. The effect is dose-independent between
10 
*9 1000 mglday'.There are few complications seen. The protective effect in venous
thrombosis is not significant and in arterial thrombosis it is moiest (r0 -20%).Ticlopidine
and clopidogrel (IscoverrM, PlavixrM) are altemative possibilities. Abciximax, the ur,iiUoay
against the fibrinogen receptor of plasma, is used in acute coronary infarction.
4. Therapeutic class review
rcular weights ranging from 1500 to 100,000 Da
:haride sequence bind to AT and catalyse the
lactors by this plasma protein. The inhibitory
rly three times that towards Factor Xa; that
ty without practical significance. The relative
ctors rs not changed by heparin, with one notable exception:
heparins smaller than 5400 Da will not cause inactivation of thrombiru but do catalyse thatof Factor Xa' Inhibition of Factor Xa is an inefficient way to inhibit thrombin formation.
LMIAIHs contain a fair amount of molecures of < 5400 Da, whe.eas uFH does not; therefore
JFH. The difference is small in the presence of
rr in the usual in aitr o test,where Ca* + is absent
deline in searching for efficient LMWHs [14].
ion this has led to useful products, because
preparations with a high-anti-Xa activity also contain a large proportion of material in the5400 - 9000 Da rimge. such material is an efficient anticoagrri#t bu"urrre of its persistent AT
rility after sc. injection I1.6,771.It has also been
ght components present in UFH, but not in
:s [18]. fn retrospect, the anti-Xa activitv must
mistaken concept. 
ue good drugs developed on the basls of a
AT only partially inhibits clot-bound thrombin, if at all. Heparin co-factor tr (HCII) [19] iscapable of inhibiting this thrombin, but only in the p.esence of relatively high corrcentra-
tions_of acid polysaccharides (dermatan sulfate, p"rrtor* polyphosphate, lactobionic acid,etc') [20-241' Heparin can also activate HCtr, but at doses much higher than the normaltherapeutic and preventive ones.
4.1 Direct thrombin inhibitors
The prototype of direct thrombin inhibitors is hiru drnl2s-281, which has proven its value inexperimental thrombosis as well as in clinical trials. Indeed direct thrombin inhibition is a
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combinatorial chemistry can construct large peptide derivative libraries and facilitate the
search for specific inhibitors 134,351. There is also continuous interest in natural inhibitors
from haematophagous animals and other sources 136-401, CVS1123 [41], inogatran
(HA-3142n[4244l,melagatran (H-31968) l4244and napsagatran (Ro-46-6240)1481, and a
large variety of others 149-651. Some have been tested in the clinical situation. Most of them
are administered parenterally, but oral administration is feasible [66]. The overall impres-
sion is that, like hirudin, they can replace heparin, without showing obvious advantages
except their use in AT deficiency and their ability to inactivate clot-bound thrombin
1M,49,67,681.
There is an essential difference between irreversible thrombin inhibitors (such as hirudin)
and reversible ones (such as argatroban [NovastanrM]). The irreversible ones bind with L:L
stoichiometry to thrombin. If drug administration is stopped, the inactivated thrombin
molecules remain inhibited. Serious bleeding problems are to be expected as soon as the
concentration of an irreversible inhibitor approaches the level of prothrombin in plasma
(-ZttM), so that all the thrombin that can be formed is immediately inhibited. Reversible
inhibitors bind a fraction of the available thrombin; the proportion inhibited is dependent
upon the inhibition constant (K = the concentration at which half-maximal inhibition is
observed) and upon the concenkation of the inhibitor. If the concentration of the inhibitor
decreases, the inhibition is relieved. Reversible inhibitors probably act because they
diminish thrombin concentration at the site of thrombosis, where thrombin formation is
triggered. They will enter into competition with the natural substrates of thrombin
(procoagulants: e.9., fibrinogen; Factors V, VlI, XI; platelets, as well as anticoagulants: e.9.,
thrombomodulin). All reversibly inhibited thrombin molecules willbe eventually released
and taken over by natural, irreversible inhibitors (e.g., AT). So, irreversible inhibitors arrest
thrombin action and reversible ones dampen it. Both mechanisms seem to lead to
antithrombotic activities. It is unknown to the authors whether there are fundamental
differences in haemorrhagic properties.
4.2 Dir ect inhibitors of other clotting enzymes
A large number of natural and synthetic inhibitors of Factor Xa has been described
[35,69-86]. The original idea behind their development was that it is more efficient to inhibit
thrombin production ('closing the tap') than thrombin itself ('mopping the floor'). This
view, based upon the early concepts of the clotting cascade as a linear mechanism, became
untenable as soon as it was realised how important thrombin-mediated feedback reactions
are and how important Factor Xa is for the inhibition of the TF Factor VIIa complex
(TF-VIIa) aia trssue factor pathway inhibitor (TFPI). Also, Factor Xa has to be inhibited by
90"/" in order to inhibit prothrombin conversion by about 50%.
Inhibition of the first step in thrombin generation, i.e., at the level of Factor VIIa and TF, is
also possible 187-891. An interesting concept is the inhibition of TF by the administration of
recombinant, active site-inhibited Factor Vtr al9o-921, or by peptides that mimic part of this
molecule [93].
All VIIa and Xa inhibitors tested appear capable of inhibiting experimental thrombosis
(e.g., [94-96]). Th"y have not yet been used in the clinic, and it is not established whether
they show specific advantages. However, an important finding has recently been made that
shows that circulating TF plays a role in the formation of the thrombus [170]. A competitive
VIIa ffiibitor could inhibit this thrombus formation. Theoreticall/, this approach towards
thrombus prevention would have a broad therapeutic range since the amount of circulating
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TF is much easier to inhibit than the local TF exposure after vessel damage, thus minimising
bleeding risk.
The main result from research on direct inhibitors as a group is that any inhibitor of the
clotting system, independent of the enzyme that it attacks or of the mode of inhibition is
antithrombotic, in any thrombosis model.
4.3 Platelet inhibitors
Maty excellent reviews on platelet inhibitors have been published I e.g.,97 ,98].Aspirin, in
all probability, acts by irreversibly inhibiting cyclooxygenase and, thereby, platelet
thromboxane ,A2 (TXA2) synthesis [99]. Other non-steroidal anti-inflammatory drugs
(NSAIDs) and sulfinpyrazoneinhibitthe same enzyme reversibly. Dipyridamole increases
intraplatelet cyclic AMP (cAMP) [99-107], as do prostaglandin E1 and prostacyclin (which,
due to its instabilitp is of limited therapeutic use) [102,103]. Stabte analogues of the latter
are iloprost (SH-401) [104,105] and ciprostene (U-61431F) [105]. Thromboxane synthase
inhibitors and inhibitors of the thromboxane receptor are of doubtful efficiency [102].
Ketanserin, one of the group of serotonin receptor antagonists seems to do no better
[108,109].
Inhibitors of the ADP receptor, such as ticlopidine [110-113] or clopidogrel [114], are better
than aspirin and may be combined with it. lrhibitors of the platelet fibrinogen receptor
glycoprotein (GP) ft/ma have shown promising results [115-119].
Platelet inhibitors have been developed as inhibitors of adhesion or aggregation. Recently,
it appeared that all those tested hitherto also inhibit thrombin generation in PRP. Aspirin,
for example, causes an inhibition of about 107o, roughly equal to the reduction of arterial
thrombosis that is seen in large clinical trials. Prostacyclin analogues also inhibit *rrombin
generation in PRP [120] (unpublished observations). Inhibition of GP IIblIIIa, the
fibrinogen receptor of the platelet membrane, reduces thrombin generation by about 50%
U21,122l Administration of these inhibitors produces the same defect as is congenitally
present in Glanzmann's thrombasthenia, a disease in which a diminution of thrombin
generationis observed [127,122]. Also,inhibitionof vonWillebrand factor (vWF),GPIb and
the vWF receptor strongly inhibits thrombin generation in PRP [729,124]. Thrombin
generation in PRP is evidently also dependent upon the function of the plasmatic clotting
factors and upon the interactions between plasma and platelets. This suggests that
thrombin generation in PRP and/or blood might be a good screening technique for
antithrombotics, independent of whether they act aia the platelet or as anticoagulants.
5. Current research goals
The ultimate research goal is an antithrombotic that decreases the incidence of thrombosis
(of any type) by more than 50%, that can be administered orallp that is immediately active,
that can be given in a standard dosage without requiring laboratory control and that does
not cause bleeding when overdosed. None of the available antithrombotics fulfil these
criteria.
The complicated HTS lends itself to inhibition at a large number of sites, each of them a
potential target for pharmacological action. The three established therapies have
completely different modes of action. Multiple other modes of inhibition have been shown
to work in experimental thrombosis. This proves that the desired goal can be attained in
many different ways. The question of what specific target in the HTS should be attacked in
@Ashley Publications Ltd. All rights reserved Emerging Drugs 1999
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order to obtain the ideal antithrombotic is often posed. It is mostly answered a prioriby
theoretical considerations that need to be corroborated a posteriori by animal thrombosis
experiments. The result, as stated, is that any inhibition entails antithrombotic activity.
Advanced knowledge of the subsystems of the HTS may, in the long run, give the answer.
This goal is not within easy reach however. At this moment it would be more useful to
conceive of a screening test that represents total HTS function, and that is simpler and less
expensive than animal thrombosis models.
s.t Laboratory models for the function of the HTS
The ideal model, like real thrombosis, should respond in a similar way to clinically effective
concentrations of all antithrombotics independent of the moleculr focus of their effect. This
means that clotting times in PRP (and afortioi inhibition tests of individual clotting factors),
platelet aggregation or adhesion tests carried out in anticoagulated PRP, are not reasonable
options. Inview of theirwidespread use, wewillnevertheless discuss clotting times inrnore
detail.
5.2 Clotting times
Blood (plasma) clots when more than 95% of the prothrombin is still to be converted [120].
Clotting tirnes do not reflect the amount of thrombin that is still to be formed at the moment
of clotting. Yet it is the amount of thrombin that determines the extent of the thrombotic
reaction. Therefore, a clotting time will not reflect directly the relevant parameter. This is
also seen from the fact that a different type of clotting time is required for estimating the
effect of different types of anticoagulants. The thromboplastin time or'prothrombin time'
(PT), for example, indicates the depth of oral anticoagulation but is not sensitive to the effect
of heparin. The aPTT is particularly sensitive to variations in the concentration and/or
activity of Factor VItr and UFH, but not to LMWH and activators of HCtr. Doubling the
aPTT is thought to represent adequate heparin administration. This is based on very limited
studies in animals [125] and rnart 1126,1271. There is no relation between recurrent
thromboembolism and the aPTT response [128]. The mechanisrn by which direct thrombin
or Factor Xa inhibitors prolong the aPTT is significantly different from that of heparin [L29].
Nevertheless 'doubling the aPTT' is also used as an indicator for therapeutic action with
any type of clotting inhibitor. We conclude that clotting tests are not a valid general
indicator of antithrombotic action. This does not mean that they cannot be used in special
cases: the thromboplastin time is a good indicator of oral anticoagulation [130] and the
Ecarin time is useful in assessing the level of direct thrombin inhibitors 1131,1321.
5.3 Platelet tests
Platelet aggregation and flow-chamber or other tests that are carried out on washed
platelets or on PRP in which the coagulation mechanism has been inhibited, will not reflect
interactions between platelets and the clotting system, and therefore are of limited use
[133-135]. Experiments in which non-anticoagulated blood is passed through a flow
chamber containing a thrombogenic surface are not subject to this drawback. A model
system that tries to mimic the concert of thrombotic triggers and flow parameters has been
developed [136-1.40]. A flow chamber is directly coupled to the antecubital vein of a
volunteer, and flow of non-anticoagulated blood is metered by a peristaltic PumP. The flow
chamber contains a piece of the media of a pig aorta, cultured endothelial cells, smooth
muscle cells or collagen-coated surfaces and human atherosclerotic plaques. After the
experiment, the exposed material will be stained and examined for platelet and fibrin
deposition. Drugs can be administered and tested for antithrombotic properbies. This
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model for tfuombosis has proven to be a workable system that closely mimics physiologic
reality under standardised conditions.
5.4 The thrombin generation curve
The thrombin generation curve (TGC), one of the oldest tools of the clotting trade, has lately
become the subject of renewed interest 115,74,120,122-124,141,-41. It contains all the
relevant information on the physiological function of the coagulation system. The area
under the curve (the endogenous thrombin potential (ETP) [142]) represents the total
enzymatic action that thrombin can develop during its lifetime in plasma. In blood and in
PRP, theETP canbe measured from aTGC obtainedby subsampling.If a substrate withthe
right kinetic properties is added to plasma, thrombin generation can be monitored continu-
ously as the first derivative of the product-time curve. At this moment, only chromogenic
substrates have been described for this use so that the method is restricted to defibrinated
PRP.
We demonstrated that higher than normal ETP is seen in all blood-based thrombosis-prone
states tested, eithercongenital (e.g., deficiency of AT,proteinS orproteinC, factorVLeiden,
prothrombin2O2l0A) or acquired (e.g., from the use of contraceptive pills). In coronary
infarction, months after the acute phase as well as in patients presenting with a deep vein
thrombosis, the ETP is increased . In the haemophilias (deficiency of Factors VII,IX and XI)
the ETP is significantly lower than normal [145].
OAC treatment (INR = 1.5 - 3.0) decreases the ETP to2O - 40% of normal. Heparin admini-
stration in the therapeutic range has the same effect. The ETP also accurately reflects the
effect of mixed OAC and heparin treatment. Platelet aggregation inhibitors diminish
thrombin generation in PRP. In fact, we encountered no anticoagulant that would not
decrease the ETP in PRP, and no antiplatelet agent that would not inhibit the ETP in PRP.
This made us think that the ETP in PRP mightbe a useful model for antithrombotic action.
6. Scientific rationale
The HTS is traditionally seen as the result of the sequential action of primary and secondary
haemostasis. The first, reflected in the bleeding time, is considered to be a platelet function
and its overshoot is the arterial, platelet-rich thrombus. The second is seen as an activity of
the plasmatic clotting mechanism; the plasma clotting time is considered the relevant test
and venous thrombosis the pathological derailment.
The separation has been artificially stressed because platelet adhesion and aggregation are
studied in anticoagulated blood, and clotting in platelet-free plasma. Under these experi-
mental circumstances the co-operation between platelets and coagulation is artificially
prevented. The impressive increase of our knowledge of the details of the clotting
mechanism and platelet function tends to favour further subdivision. This is reflected in
drug research. Not only is a sharp distinction made between anticoagulants and platelet
inhibitors, but often a more restricted target is defined (e.g., Factor VIIan or G-proteins) and
screening is for an action on that target rather than on global functioning of the HTS.
It is becoming increasingly clear that,inaiao,the HTS functions by the concerted action of
platelets and plasma, rather than as a consequence of an adhesion-aggregation function of
the platelets and a clotting function of the plasma (Figure 1). Thrombin is the most potent
platelet activator, and platelet activation is essential for thrombin generation.
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Figure 1: Outlines of the interactions between the coagulation system and the platelet glycoprotein (GP) IIb/IIIa
and GPIb receptors (from[123]).
VIVF: von Willebrand factor.
Anticoagulants inhibit arterial as well as venous thrombosis I14f,L n- Phtelet inhibitors
inhibit thrombin generation in PRP, etc.
This is not the place to discuss the mechanisms in detail. We refer to books and review
articles for this p.tnpor". FIere we only sketch outlines, together with some recent findings
that may have an important bearing on drug development.
In the plasmatic coagulation system, Factor Xa is formed by the action of the TF-VIIa. Factor
Xa binds to TFPI, and the TFPI-Xa complex inhibits the TF-VIIa complex. Thrombin
activates Factors V, VIII and XI and so accelerates its own generatiory but it also binds to
thrombomodulin and so starts the protein C mechanism that breaks down Factors V and
VIII, thus indirectly inhibiting further thrombin generation. An irnportant fraction (- 30%)
of all thrombin formed in clotting plasma is bound to the fibrin clot. Clot-bound thrombin
does retain its thrombotic properties; it can clot fibrinogen, activate Factors V VItr and XI
and platelets1123,1.48,1.49l. It is not inhibited by AT and, upon fibrinolysis, it may reaPpear
in circulation.
Four different thrombin receptors have been described on the platelet membrane.
Thrombin action causes GPIIb/IIIa receptors in the platelet membrane to bind fibrinogery
which causes platelet aggregation. GPIIb/Itra activation also leads to the exposure of
procoagulant phospholipids in a vWF-dependent reactionl123,124l. These phospholipids
ure ,"qrrit"d for the proper activation of Factor X and prothrombin. Lately, the picture has
been implicated Uy Ure d.iscovery that fibriru previously thought to be the inert end
product of coagulation, plays an active role itself. It binds and activates vWF, which in tum
activates plateLts ainGPIb,and provokes the exposure of procoagulant phospholipids zla
an altemative pathwaY.
Thus, the co-operationbetween platelets and the coagulation system is central to the FITS,
and the mechanism shows an abundance of positive and negative (often nested) feedback
loops. This necessarily is a non-linear system [150]. In the most simple terms this means that
the dose-response relationships become highly unpredictable ('chaotic'). Furthermore,
thrombin generation reactions often go to completion, so that classical initial rate kinetics is
@Ashley Publications Ltd. All rights reserved
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of limited applicability. The literature abounds with studies that conjecture on antithrom-
botic effects of enzyme inhibition on the basis of oversimplified models. Extensive experi-
ence inenzyme kinetics tells us thatourknowledge of the system (and of non-linear systems
in general) is simply insufficient to predict such effects. We may be glad if we can
understand certain phenomena a posteiori.
An example is the much-debated issue of inhibition of Factor Xa. The original idea was that
it was more efficient to inhibit the prothrombin-converting enzyme (Factor Xa) than the
product (thrombin) [151,152]. This seemed a very logical idea until it was fully recognised
that, under physiological circumstances, Factor Xa requires thrombin-activated Factor V to
increase its tumover number [154], and needs adsorption onto procoagulant phospholipid
to decrease its K* below the plasma concentration of prothrombin [1531. The amount of
prothrombin-converting complex that can be maximally formed is not higher than the
scarcestcomponent. InPRP, withadequate amounts of phospholipid added, it is easily seen
that the rate-limiting component is not Factor Xa. The reasons are:
o the plasma concentration of Factor X is approx. 120 nM, whilst that of Factor V is approx.
20 n\zl, which may rise to 40 nM if the platelets release their Factor V [155]
. the serum concentration of Factor X is considerable ('stable factor'), whereas that of Fac-
tor V is near to zero ('labile factor')
. decrease of the Factor Va concentratronaia the APC system efficiently limits prothrom-
bin conversion.
In PRP, the rate limiting component is neither Factor Va nor Factor Xa, but the exposure of
procoagulant phospholipids by the platelets [120]. Still closer to real life, if the procoagulant
phospholipid surface is much larger than the molecules involved, as in the case of platelets
sticking to a wounded surface, the reaction is diffusion-limited and therefore no longer
dependent even upon the concentration of the prothrombinase complex on the surface.
Only the concentration of prothrombin in the plasma counts [156-158]. Therefore, there are
many arguments to show that, in clotting plasma, Factor Xa is available in excess and has to
be inhibited by 90% in order to inhibit prothrombinase activity by 50"/".
Still, it is often argued that one can expect from direct Factor Xa inhibition an efficacy:safety
ratio superior to that achieved by inhibiting thrombin once it is formed. There is no rational
theoretical basis for this statement as soon as one realises the importance of thrombin-
mediated feedback reactions, and the excess of Factor Xa present in clotting plasma. This
does not mean to say that Factor Xa inhibition may not be the mechanismaia which good
antithrombotic efficiency can be obtained. If it is pushed far enough it may certainly cause
inhibition of prothrombin conversion. It is only meant as an illustration that predictions on
the basis of available theory are precarious. At a previous state of knowledge, one would
expect a benefit of Factor Xa inhibition. At present, one would rather predict a narrow
therapeutic m argin (aiz. that between 90 - 100% inhibition of Factor X). It is the very essence
of this article to show that even sophisticated theoretical arguments cannot predict the ln
aiaobehaviour of an antithrombotic, but that a physiological test of the overall function of
the HTS is needed instead. Nevertheless, it is a rewarding operation to refute theoretical
considerations that are no longer up-to-date, but that tend to survive in pharmaceutical
circles.
The proof of the pudding will remain in the eating. It has been shown that thrombin genera-
tion can be effectively inhibited by the injection of the pentasaccharide with anti-Factor Xa
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activity [159]. This pentasaccharide (Sanofi ISP/901071; Organon [Org315 0]) is now in
Phase II clinical trials. DX9055a (Daiichi) is in Phase I clinical trial and TFPI SC59735 is in
Phase II. If there are any specific advantages of Factor Xa inhibition they will be seen in such
studies.
2.1 Catalysts of physiological inhibition
7.1.1 Purer preparntions of the active fractions wilhin natural heparins
Heparins, as they are presently obtained from natural sources, are highly heterogeneous
[14j. Apart from the anticoagulant molecules, there is 50 
- 80% of other material that is not
necessirily without biological action. Also, it has been postulated on good grounds that
material with a molecular weight lower than 5400 is much less active than higher molecular
weight material l16}-1,62l,whereas material larger than about 9000 has an extremely low
bioavailability [15]. In addition, it might be more haemorrhagic than lower molecular
weight material [18].
7.1.2 Synthetic heparins
It has been an important achievement of Petitou (within the Choay group) to synthesise the
pentasaccharide that is responsible for high affinity ATbinding in natural heparins. Later
research in the Sanofi and Organon teams has led to variants with higher activity 1763'1'&1.
These materials have anti-Xa activity only. High doses can be givery however, so that
thrombin generation can be inhibited in this way. In view of the much greater efficiency of
AT action than of anti-Xa activity, it is to be expected that heparins in which a long inert
glycosaminoglycan chain is attached to the active pentasaccharide would make a pure and
very active heparin.
7.1.3 Activators of heparin co-Factor II
Dermatan sulfate and pentosan polyphosphate are long since known as antithrombotics
[20,164,165]. These drugs have the drawback that concentrations above the micromolar
range have to be administered, which at a molecular weight of 10,000 to 100,000 requires
administration of large amounts of therapeutic material. The development of pure, low
molecular weight material should be considered. There is only 1 pM HCtr in plasma. This is
lower than the level of prothrombin (2 pM). Optimal activation of all HCtr will not exhaust
the thrombin-forming capacity of the plasma. Unlike heparin, which acts on 2.4 pM AT,
activators of HCtr cannot, therefore, be overdosed to cause bleeding.
A special class of substances, the thioxylosides, is capable of altering synthetic reactions in
the body of glycosaminoglycans that interact with HCtr. Administration of these drugs
raises the level of glycosaminoglycans in the plasma, and in this way activate HCII
11.66,1671.
t.2Direct inhibitors
Enormous progress has been made in our understanding of the stereochemistry of clotting
enzymes lf OS]. ftris,togetherwithmodemtechniques of organic synthesis and screening of
itrhiUitory activity [34], has provided us with a number of highly specific inhibitors of
individual clotting enzymes, and no doubt more are to come. Sanderson and Naylor-Olsen
[L69] recently published an excellent review on thrombin inhibitor design, to which we
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refer you for details. The hope is that from this line of research a compound will be identi-
fied that can be administered orally, and that has pharmacokinetic properties which allow
standard dosage without control. Evidentlp one of the problemrlr U,r" large amount of
serine proteases present in the intestinal tract.
Itwillbe clearfromthe above discussionthat, in our opiniory there is nopredictable relation
between the biochemical mode of action of these inhibitors and thl pharmacological
efficiency. Elg et aI. compared the kinetic constants of eight different direct thrombin inhibi-
tors and saw that, despite a 50,000-fold difference in X(i value, hirudin and melagatran had
similar antithrombotic effects at around 0.14 pM plasma concentration [129]. These authors
did report a relation between kor. and the slope of the dose-response curye of thrombus
inhi-bition. ftr theory a steeper slope indicates a narrower therapeutic interval. To judge
inhibitors on this criterion does not seem realistic, however, as long as we are not certain
that the pharmacokinetics allow maintenance of stable plasma levels and, more
importantly, as long as the dose-response of haemorrhage is ntt known.
7.3 Platelet inhibitors
At this moment, there are no inhibitors in clinical use that attack aia Gp Ib /Ix,the receptor
absent in Bemard-Soulier's disease. Antibodies against this inhibitor also strongty 1-SOn1
inhibit thrombin generation. A combination of antibodies against both the Gp Ib and the Gp
Ilb/fra/nla receptors will almost completely abolish thrombin generation in pRp. vWF
has been shown to be a necessary co-factor for both receptors; consequently, in the absence
of this factor thrombin generation is almost nil, independent of the availaUility of Factor
VIII. This suggests that interfering with these interactions can be an efficient means of
antithrombotic action.
We saw that fibrin can play an active role in the development of platelet procoagulant
activity, and hence in thrombin generation and furthei thrombus 9.o*6. It m"ay be
interesting to try and find inhibitors of the (vWF-mediated) platelet-fibrin interaclion,
which might lead to early pacification of a growing thrombus. 
-
s. Editorial analvsis
Lr the search for new and better antithrombotics, the open options are as big as the number
of vulnerable sites in the HTS (i.e., every enzyme and every receptor involved) multiplied
by the number of compounds that can inhibit each site). It is hard to believe that theldeal
antithrombotic is not there to be found. The question is how to find it. The present strategy is
to first define a subsystem of interest within the HTS; this clotting factor, that membiane
receptor' Then a test is set up for that subsystem. Prornising compounds are selected on the
basis of their performance in that test. Such .o.nporlnd, are then tested. in animal
thrombosis models and may make it to the phases of investigation in humans.
The problem lies in the choice of the subsystem to be tested. Clotting times and platelet
aggregation/adhesion assays are only of limited use because they do not reflect inturu"-
tions between platelets and the clotting system, recently shown to be extremely important.
More specific tests on individual clotting factors or platelet functions are even less fit for the
task. The risk is that we find inhibitors of an irrelevant test, and pass by good antithrom-
botics that do not inhibit this test. The example of LMWHs is a good iltustration. These
drugs were developed upon the criterion of Factor Xa inhibitioru which later was shown to
be of no relevance. Later research showed that the performance of these drugs is 4ue to
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thrombin-inhibition together with high bioavailabilrty and, probably, absence of large
molecular weight molecules that induce bleeding'
Therefore, there is an obvious need. for a representative, functional test of the HTS' This test
should respond quantitatively in the same manner to any antithrombotic given at a dosage
within its therapeutic window. It should, for example, be equally sensitive to doses 
of
antiplatelet drugs and anticoagulants of comparable efficacy.
There are two tests in which the interaction between platelets and plasma is not artificially
disrupted: thrombin generation in PRP (or whole blood), and flow chamber experiments 
in
which non-anticoaguiated humanblood is d.rawn over a thrombogenic surface' Both tests
require much development. In our opinion, progress in technical development of this type
of test would be a major step forward in the search for the ideal anticoagulant'
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